OmanDocSign in

Curriculum · Musculoskeletal / Orthopedic / Rheumatology

Methotrexate monitoring

What it is

Methotrexate is a disease-modifying antirheumatic drug (DMARD) and a purine antimetabolite. In rheumatoid arthritis it is the DMARD given first, with hydroxychloroquine second, and it is taken once weekly rather than every day. The same drug turns up in many other diseases: as a systemic treatment in psoriasis, as the long-term immunosuppressant therapy that follows steroids in polymyositis and dermatomyositis, in low dose with prednisone, on limited evidence, for the skin disease of systemic sclerosis, for maintaining remission in JIA, as CNS prophylaxis in acute lymphoblastic leukemia where it is given intrathecal or systemic, and as single dose medical treatment for ectopic pregnancy. For patients who are intolerant to methotrexate the alternative treatments are leflunomide and sulfasalazine.

The ectopic pregnancy protocol sets out how it works: methotrexate is a folic acid antagonist that inactivates dihydrofolate reductase and the de novo synthesis of purines and pyrimidines, and therefore cellular DNA, so it acts on rapidly dividing trophoblastic cells and prevents their multiplication.

How it is treated

Before the drug is started, safety screening covers liver, kidney, blood counts, hepatitis B and C serology, evidence of lung disease, liver disease, alcohol use, and pregnancy. Where methotrexate is used to maintain remission in JIA, the monitoring is written as RFT and LFT. For ectopic pregnancy the single dose medical treatment protocol sets the monitoring out day by day:

If the decline in serum B-hCG on Day 7 from Day 4 is 15% or more, no further treatment is required and B-hCG levels are repeated weekly. If the decline is under 15%, or fetal cardiac activity is present, the methotrexate dose is repeated and a new Day 1 begins. Surgical treatment is offered if the B-hCG level did not fall by two doses of methotrexate, or if fetal cardiac activity persists. Until the ectopic pregnancy is resolved, sexual intercourse is prohibited, alcohol should be avoided, and folic acid supplements, including prenatal vitamins, should not be taken.

Before that protocol runs, the indications for medical management are a clinically stable patient with a beta HCG level below 5000 IU/L, with 5000 to 10,000 at the consultant's discretion; an adnexal mass up to 40mm; and absence of foetal cardiac activity. Informed consent after appropriate counseling covers pain, the failure rate, the possibility of emergency surgery at any time, the need for another injection, and follow-up. Complete blood count, renal function and liver function test are done before methotrexate is given.

Where the drop is more than 15% between day 4 and day 7, beta HCG is repeated weekly until it is below 10-20 IU/L. The point at which surgery is offered is reported differently: one source offers surgical treatment if the beta HCG level did not fall by two doses of methotrexate, and another after three doses.

A worked follow up shows what failure looks like: B-hCG of 1000 on Day 1, 1200 on Day 4 and 2200 on Day 7, that is a rise and not a fall.

Monitoring on methotrexate is CBC for bone marrow suppression, LFTs for hepatotoxicity, and renal function to adjust the dose. Folic acid 1-5 mg/week is given to reduce side effects, and methotrexate is avoided in pregnancy and in alcohol abuse. The other drugs on the same sheet differ. Hydroxychloroquine needs a baseline eye exam then annual screening after 5 years, or earlier if the risk is high, with OCT and visual fields for maculopathy, and the risk rises with a dose above 5 mg/kg/day or with renal disease. Azathioprine needs CBC for leukopenia, LFTs, and a TPMT level before starting to check metabolism capacity, and allopurinol is to be avoided. Mycophenolate mofetil needs CBC especially for neutropenia, with LFTs and renal function, and is contraindicated in pregnancy as a teratogenic drug. Cyclophosphamide needs CBC for myelosuppression, urinalysis for hematuria and bladder toxicity, and LFTs.